Disease-modifying drugs for multiple sclerosis must be globally available according to therapeutic guidelines suitable to different regions of the world. Sá M J Arq Neuropsiquiatr. 2012 Oct; 70(10):761-2. PMID: 23060099. Abstract CommentRecommendBookmarkWatch